CA2660516A1 - Traitement ou prevention de cancers surexprimant le reg4 ou le kiaa0101 - Google Patents

Traitement ou prevention de cancers surexprimant le reg4 ou le kiaa0101 Download PDF

Info

Publication number: CA2660516A1
Authority: CA; Canada
Prior art keywords: seq; reg4; polypeptide; cancer; cell
Prior art date: 2006-08-18
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2660516

Other languages

English (en)

Inventor

Yusuke Nakamura

Hidewaki Nakagawa

Shuichi Nakatsuru

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Oncotherapy Science Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-08-18

Filing date

2007-08-08

Publication date

2008-02-21

2007-08-08 Application filed by Individual filed Critical Individual

2008-02-21 Publication of CA2660516A1 publication Critical patent/CA2660516A1/fr

Status Abandoned legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 141
210000004027 cell Anatomy 0.000 claims abstract description 409
101001096074 Homo sapiens Regenerating islet-derived protein 4 Proteins 0.000 claims abstract description 326
102100037889 Regenerating islet-derived protein 4 Human genes 0.000 claims abstract description 298
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 226
101000585555 Homo sapiens PCNA-associated factor Proteins 0.000 claims abstract description 190
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 181
108090000623 proteins and genes Proteins 0.000 claims abstract description 175
102100029879 PCNA-associated factor Human genes 0.000 claims abstract description 172
230000014509 gene expression Effects 0.000 claims abstract description 165
229920001184 polypeptide Polymers 0.000 claims abstract description 160
238000000034 method Methods 0.000 claims abstract description 158
108020004459 Small interfering RNA Proteins 0.000 claims abstract description 133
206010061902 Pancreatic neoplasm Diseases 0.000 claims abstract description 101
102000004169 proteins and genes Human genes 0.000 claims abstract description 101
201000011510 cancer Diseases 0.000 claims abstract description 100
201000002528 pancreatic cancer Diseases 0.000 claims abstract description 97
208000008443 pancreatic carcinoma Diseases 0.000 claims abstract description 97
208000015486 malignant pancreatic neoplasm Diseases 0.000 claims abstract description 96
150000007523 nucleic acids Chemical group 0.000 claims abstract description 90
201000008129 pancreatic ductal adenocarcinoma Diseases 0.000 claims abstract description 72
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 70
239000000203 mixture Substances 0.000 claims abstract description 63
239000013598 vector Substances 0.000 claims abstract description 60
239000012634 fragment Substances 0.000 claims abstract description 58
239000003795 chemical substances by application Substances 0.000 claims abstract description 38
230000001225 therapeutic effect Effects 0.000 claims abstract description 36
238000011127 radiochemotherapy Methods 0.000 claims abstract description 24
208000026310 Breast neoplasm Diseases 0.000 claims abstract description 23
206010060862 Prostate cancer Diseases 0.000 claims abstract description 23
208000000236 Prostatic Neoplasms Diseases 0.000 claims abstract description 23
208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims abstract description 23
206010005003 Bladder cancer Diseases 0.000 claims abstract description 22
206010006187 Breast cancer Diseases 0.000 claims abstract description 22
201000005112 urinary bladder cancer Diseases 0.000 claims abstract description 22
108010011110 polyarginine Proteins 0.000 claims abstract description 7
239000004055 small Interfering RNA Substances 0.000 claims description 133
230000000694 effects Effects 0.000 claims description 81
125000003729 nucleotide group Chemical group 0.000 claims description 80
239000002773 nucleotide Substances 0.000 claims description 78
102000039446 nucleic acids Human genes 0.000 claims description 67
108020004707 nucleic acids Proteins 0.000 claims description 67
241000282414 Homo sapiens Species 0.000 claims description 63
230000000692 anti-sense effect Effects 0.000 claims description 49
102000040430 polynucleotide Human genes 0.000 claims description 41
108091033319 polynucleotide Proteins 0.000 claims description 41
239000002157 polynucleotide Substances 0.000 claims description 41
230000000295 complement effect Effects 0.000 claims description 36
239000008194 pharmaceutical composition Substances 0.000 claims description 36
108091081021 Sense strand Proteins 0.000 claims description 30
239000000126 substance Substances 0.000 claims description 29
238000004519 manufacturing process Methods 0.000 claims description 27
108091028664 Ribonucleotide Proteins 0.000 claims description 25
239000002336 ribonucleotide Substances 0.000 claims description 25
239000004480 active ingredient Substances 0.000 claims description 24
239000012472 biological sample Substances 0.000 claims description 23
125000002652 ribonucleotide group Chemical group 0.000 claims description 23
230000004663 cell proliferation Effects 0.000 claims description 22
210000000170 cell membrane Anatomy 0.000 claims description 21
108091028043 Nucleic acid sequence Proteins 0.000 claims description 20
108091034117 Oligonucleotide Proteins 0.000 claims description 20
230000008827 biological function Effects 0.000 claims description 16
230000001965 increasing effect Effects 0.000 claims description 13
239000003937 drug carrier Substances 0.000 claims description 12
230000003305 autocrine Effects 0.000 claims description 9
230000003076 paracrine Effects 0.000 claims description 9
238000004113 cell culture Methods 0.000 claims description 7
230000008569 process Effects 0.000 claims description 6
102100036976 X-ray repair cross-complementing protein 6 Human genes 0.000 claims description 5
101710124907 X-ray repair cross-complementing protein 6 Proteins 0.000 claims description 5
UKVZSPHYQJNTOU-GQJPYGCMSA-N (2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-5-amino-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-amino-3-hydroxybutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]acetyl]amino]-4-methylpentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]acetyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]-5-carbamimidamidopentanoyl]amino]hexanoic acid Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-GQJPYGCMSA-N 0.000 claims description 3
108010062307 AAVALLPAVLLALLAP Proteins 0.000 claims description 3
101800002011 Amphipathic peptide Proteins 0.000 claims description 3
102100028072 Fibroblast growth factor 4 Human genes 0.000 claims description 3
108010061875 HN-1 peptide Proteins 0.000 claims description 3
101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 claims description 3
108700003968 Human immunodeficiency virus 1 tat peptide (49-57) Proteins 0.000 claims description 3
108010088535 Pep-1 peptide Proteins 0.000 claims description 3
102000029797 Prion Human genes 0.000 claims description 3
108091000054 Prion Proteins 0.000 claims description 3
101710149951 Protein Tat Proteins 0.000 claims description 3
108010025307 buforin II Proteins 0.000 claims description 3
UKVZSPHYQJNTOU-IVBHRGSNSA-N chembl1240717 Chemical compound C([C@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](N)[C@H](C)O)CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 UKVZSPHYQJNTOU-IVBHRGSNSA-N 0.000 claims description 3
BHONFOAYRQZPKZ-LCLOTLQISA-N chembl269478 Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(O)=O)C1=CC=CC=C1 BHONFOAYRQZPKZ-LCLOTLQISA-N 0.000 claims description 3
108010043655 penetratin Proteins 0.000 claims description 3
MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 claims description 3
PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 claims description 3
108010062760 transportan Proteins 0.000 claims description 3
238000012258 culturing Methods 0.000 claims description 2
230000002401 inhibitory effect Effects 0.000 abstract description 35
230000012010 growth Effects 0.000 abstract description 21
239000003814 drug Substances 0.000 abstract description 18
238000001890 transfection Methods 0.000 abstract description 14
210000004881 tumor cell Anatomy 0.000 abstract description 8
229940124597 therapeutic agent Drugs 0.000 abstract description 2
235000018102 proteins Nutrition 0.000 description 96
230000027455 binding Effects 0.000 description 66
238000011282 treatment Methods 0.000 description 61
108020004414 DNA Proteins 0.000 description 60
229920002477 rna polymer Polymers 0.000 description 51
108050006400 Cyclin Proteins 0.000 description 45
102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 45
230000010261 cell growth Effects 0.000 description 40
239000000427 antigen Substances 0.000 description 39
102000036639 antigens Human genes 0.000 description 39
108091007433 antigens Proteins 0.000 description 39
230000006870 function Effects 0.000 description 35
102100027824 3'(2'),5'-bisphosphate nucleotidase 1 Human genes 0.000 description 29
108010047041 Complementarity Determining Regions Proteins 0.000 description 29
150000001875 compounds Chemical class 0.000 description 29
210000001519 tissue Anatomy 0.000 description 26
108060003951 Immunoglobulin Proteins 0.000 description 25
102000018358 immunoglobulin Human genes 0.000 description 25
230000003472 neutralizing effect Effects 0.000 description 25
102000014914 Carrier Proteins Human genes 0.000 description 23
108091008324 binding proteins Proteins 0.000 description 23
238000001415 gene therapy Methods 0.000 description 23
BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 22
238000001727 in vivo Methods 0.000 description 22
230000003993 interaction Effects 0.000 description 22
241000699666 Mus <mouse, genus> Species 0.000 description 21
235000001014 amino acid Nutrition 0.000 description 21
230000002018 overexpression Effects 0.000 description 21
239000000047 product Substances 0.000 description 21
241001465754 Metazoa Species 0.000 description 20
238000003197 gene knockdown Methods 0.000 description 20
238000000338 in vitro Methods 0.000 description 20
108020004999 messenger RNA Proteins 0.000 description 20
150000001413 amino acids Chemical class 0.000 description 19
239000002299 complementary DNA Substances 0.000 description 19
230000006907 apoptotic process Effects 0.000 description 18
230000005764 inhibitory process Effects 0.000 description 18
229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
238000009472 formulation Methods 0.000 description 17
230000004048 modification Effects 0.000 description 17
238000012986 modification Methods 0.000 description 17
238000002560 therapeutic procedure Methods 0.000 description 17
201000010099 disease Diseases 0.000 description 16
239000000523 sample Substances 0.000 description 16
238000010186 staining Methods 0.000 description 16
238000003556 assay Methods 0.000 description 15
229960005277 gemcitabine Drugs 0.000 description 15
238000002347 injection Methods 0.000 description 15
239000007924 injection Substances 0.000 description 15
SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 14
238000009396 hybridization Methods 0.000 description 14
230000002163 immunogen Effects 0.000 description 14
239000003446 ligand Substances 0.000 description 14
239000002609 medium Substances 0.000 description 14
239000000243 solution Substances 0.000 description 14
239000013604 expression vector Substances 0.000 description 13
229940072221 immunoglobulins Drugs 0.000 description 13
230000001939 inductive effect Effects 0.000 description 13
230000009467 reduction Effects 0.000 description 13
230000014616 translation Effects 0.000 description 13
238000001262 western blot Methods 0.000 description 13
238000000134 MTT assay Methods 0.000 description 12
231100000002 MTT assay Toxicity 0.000 description 12
241000124008 Mammalia Species 0.000 description 12
108091027967 Small hairpin RNA Proteins 0.000 description 12
239000002671 adjuvant Substances 0.000 description 12
239000001963 growth medium Substances 0.000 description 12
230000001404 mediated effect Effects 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
238000013519 translation Methods 0.000 description 12
108010021625 Immunoglobulin Fragments Proteins 0.000 description 11
102000008394 Immunoglobulin Fragments Human genes 0.000 description 11
238000001514 detection method Methods 0.000 description 11
210000004408 hybridoma Anatomy 0.000 description 11
238000012360 testing method Methods 0.000 description 11
241000701161 unidentified adenovirus Species 0.000 description 11
108091032973 (ribonucleotides)n+m Proteins 0.000 description 10
102000040650 (ribonucleotides)n+m Human genes 0.000 description 10
238000002835 absorbance Methods 0.000 description 10
238000004458 analytical method Methods 0.000 description 10
108020001507 fusion proteins Proteins 0.000 description 10
102000037865 fusion proteins Human genes 0.000 description 10
238000001114 immunoprecipitation Methods 0.000 description 10
230000001976 improved effect Effects 0.000 description 10
238000003757 reverse transcription PCR Methods 0.000 description 10
210000000130 stem cell Anatomy 0.000 description 10
239000003826 tablet Substances 0.000 description 10
238000013518 transcription Methods 0.000 description 10
230000035897 transcription Effects 0.000 description 10
206010035226 Plasma cell myeloma Diseases 0.000 description 9
241000700159 Rattus Species 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
230000000875 corresponding effect Effects 0.000 description 9
210000002919 epithelial cell Anatomy 0.000 description 9
238000002474 experimental method Methods 0.000 description 9
239000000499 gel Substances 0.000 description 9
239000007788 liquid Substances 0.000 description 9
201000000050 myeloid neoplasm Diseases 0.000 description 9
210000000056 organ Anatomy 0.000 description 9
239000000843 powder Substances 0.000 description 9
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 9
238000010561 standard procedure Methods 0.000 description 9
238000006467 substitution reaction Methods 0.000 description 9
239000000725 suspension Substances 0.000 description 9
CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 8
230000004543 DNA replication Effects 0.000 description 8
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical class CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
108700020796 Oncogene Proteins 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
-1 for example Proteins 0.000 description 8
238000010353 genetic engineering Methods 0.000 description 8
210000002216 heart Anatomy 0.000 description 8
230000004068 intracellular signaling Effects 0.000 description 8
210000004185 liver Anatomy 0.000 description 8
210000004072 lung Anatomy 0.000 description 8
239000003550 marker Substances 0.000 description 8
230000026731 phosphorylation Effects 0.000 description 8
238000006366 phosphorylation reaction Methods 0.000 description 8
238000003752 polymerase chain reaction Methods 0.000 description 8
230000002265 prevention Effects 0.000 description 8
230000001105 regulatory effect Effects 0.000 description 8
210000002966 serum Anatomy 0.000 description 8
230000009870 specific binding Effects 0.000 description 8
230000008685 targeting Effects 0.000 description 8
238000012546 transfer Methods 0.000 description 8
101710154606 Hemagglutinin Proteins 0.000 description 7
241000282412 Homo Species 0.000 description 7
241000283973 Oryctolagus cuniculus Species 0.000 description 7
101710093908 Outer capsid protein VP4 Proteins 0.000 description 7
101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 7
101710176177 Protein A56 Proteins 0.000 description 7
230000001594 aberrant effect Effects 0.000 description 7
210000004369 blood Anatomy 0.000 description 7
239000008280 blood Substances 0.000 description 7
230000037396 body weight Effects 0.000 description 7
230000003833 cell viability Effects 0.000 description 7
238000002512 chemotherapy Methods 0.000 description 7
230000003247 decreasing effect Effects 0.000 description 7
239000000185 hemagglutinin Substances 0.000 description 7
238000011534 incubation Methods 0.000 description 7
210000003734 kidney Anatomy 0.000 description 7
210000000496 pancreas Anatomy 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
230000019491 signal transduction Effects 0.000 description 7
239000002904 solvent Substances 0.000 description 7
208000024891 symptom Diseases 0.000 description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
230000007730 Akt signaling Effects 0.000 description 6
WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 6
102000004190 Enzymes Human genes 0.000 description 6
108090000790 Enzymes Proteins 0.000 description 6
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
241000699660 Mus musculus Species 0.000 description 6
241000699670 Mus sp. Species 0.000 description 6
238000000636 Northern blotting Methods 0.000 description 6
101710120037 Toxin CcdB Proteins 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
102000025171 antigen binding proteins Human genes 0.000 description 6
108091000831 antigen binding proteins Proteins 0.000 description 6
239000002246 antineoplastic agent Substances 0.000 description 6
238000013459 approach Methods 0.000 description 6
230000008901 benefit Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004556 brain Anatomy 0.000 description 6
239000002775 capsule Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
238000012217 deletion Methods 0.000 description 6
230000037430 deletion Effects 0.000 description 6
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
239000002552 dosage form Substances 0.000 description 6
229940088598 enzyme Drugs 0.000 description 6
239000012091 fetal bovine serum Substances 0.000 description 6
239000012530 fluid Substances 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
239000002502 liposome Substances 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
239000000463 material Substances 0.000 description 6
230000003278 mimic effect Effects 0.000 description 6
230000035772 mutation Effects 0.000 description 6
239000013642 negative control Substances 0.000 description 6
210000004940 nucleus Anatomy 0.000 description 6
238000011580 nude mouse model Methods 0.000 description 6
238000011275 oncology therapy Methods 0.000 description 6
230000037361 pathway Effects 0.000 description 6
239000002953 phosphate buffered saline Substances 0.000 description 6
239000002504 physiological saline solution Substances 0.000 description 6
239000013612 plasmid Substances 0.000 description 6
230000035755 proliferation Effects 0.000 description 6
230000001177 retroviral effect Effects 0.000 description 6
238000003786 synthesis reaction Methods 0.000 description 6
238000011144 upstream manufacturing Methods 0.000 description 6
241000283690 Bos taurus Species 0.000 description 5
241000282472 Canis lupus familiaris Species 0.000 description 5
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 5
102100024829 DNA polymerase delta catalytic subunit Human genes 0.000 description 5
241000282326 Felis catus Species 0.000 description 5
108010067306 Fibronectins Proteins 0.000 description 5
102000016359 Fibronectins Human genes 0.000 description 5
102100026121 Flap endonuclease 1 Human genes 0.000 description 5
108090000652 Flap endonucleases Proteins 0.000 description 5
108010010803 Gelatin Proteins 0.000 description 5
101000909198 Homo sapiens DNA polymerase delta catalytic subunit Proteins 0.000 description 5
108091058544 REG family proteins Proteins 0.000 description 5
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 5
238000007792 addition Methods 0.000 description 5
239000011230 binding agent Substances 0.000 description 5
230000007910 cell fusion Effects 0.000 description 5
230000007423 decrease Effects 0.000 description 5
230000001419 dependent effect Effects 0.000 description 5
235000019441 ethanol Nutrition 0.000 description 5
239000008273 gelatin Substances 0.000 description 5
229920000159 gelatin Polymers 0.000 description 5
235000019322 gelatine Nutrition 0.000 description 5
235000011852 gelatine desserts Nutrition 0.000 description 5
230000009368 gene silencing by RNA Effects 0.000 description 5
102000053579 human REG4 Human genes 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000003780 insertion Methods 0.000 description 5
230000037431 insertion Effects 0.000 description 5
210000004698 lymphocyte Anatomy 0.000 description 5
230000036961 partial effect Effects 0.000 description 5
238000004393 prognosis Methods 0.000 description 5
230000002062 proliferating effect Effects 0.000 description 5
238000012552 review Methods 0.000 description 5
239000011780 sodium chloride Substances 0.000 description 5
239000000375 suspending agent Substances 0.000 description 5
239000013603 viral vector Substances 0.000 description 5
238000005406 washing Methods 0.000 description 5
206010052747 Adenocarcinoma pancreas Diseases 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
108091026890 Coding region Proteins 0.000 description 4
102000053602 DNA Human genes 0.000 description 4
238000002965 ELISA Methods 0.000 description 4
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical class CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 4
239000004365 Protease Substances 0.000 description 4
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 4
229920002684 Sepharose Polymers 0.000 description 4
238000000692 Student's t-test Methods 0.000 description 4
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
229930006000 Sucrose Natural products 0.000 description 4
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 4
239000000654 additive Substances 0.000 description 4
238000001042 affinity chromatography Methods 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 4
238000009175 antibody therapy Methods 0.000 description 4
230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 4
210000000628 antibody-producing cell Anatomy 0.000 description 4
230000001640 apoptogenic effect Effects 0.000 description 4
230000002238 attenuated effect Effects 0.000 description 4
SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 4
230000000975 bioactive effect Effects 0.000 description 4
VTJUKNSKBAOEHE-UHFFFAOYSA-N calixarene Chemical compound COC(=O)COC1=C(CC=2C(=C(CC=3C(=C(C4)C=C(C=3)C(C)(C)C)OCC(=O)OC)C=C(C=2)C(C)(C)C)OCC(=O)OC)C=C(C(C)(C)C)C=C1CC1=C(OCC(=O)OC)C4=CC(C(C)(C)C)=C1 VTJUKNSKBAOEHE-UHFFFAOYSA-N 0.000 description 4
230000009702 cancer cell proliferation Effects 0.000 description 4
229910002092 carbon dioxide Inorganic materials 0.000 description 4
239000000969 carrier Substances 0.000 description 4
238000007385 chemical modification Methods 0.000 description 4
239000012707 chemical precursor Substances 0.000 description 4
238000004587 chromatography analysis Methods 0.000 description 4
238000010293 colony formation assay Methods 0.000 description 4
238000011161 development Methods 0.000 description 4
230000018109 developmental process Effects 0.000 description 4
229940079593 drug Drugs 0.000 description 4
239000012636 effector Substances 0.000 description 4
238000005516 engineering process Methods 0.000 description 4
238000002991 immunohistochemical analysis Methods 0.000 description 4
230000003834 intracellular effect Effects 0.000 description 4
238000007912 intraperitoneal administration Methods 0.000 description 4
239000000314 lubricant Substances 0.000 description 4
239000012139 lysis buffer Substances 0.000 description 4
238000002493 microarray Methods 0.000 description 4
238000010208 microarray analysis Methods 0.000 description 4
201000002094 pancreatic adenocarcinoma Diseases 0.000 description 4
210000004923 pancreatic tissue Anatomy 0.000 description 4
239000000137 peptide hydrolase inhibitor Substances 0.000 description 4
238000010647 peptide synthesis reaction Methods 0.000 description 4
230000035699 permeability Effects 0.000 description 4
108040007629 peroxidase activity proteins Proteins 0.000 description 4
102000013415 peroxidase activity proteins Human genes 0.000 description 4
239000000546 pharmaceutical excipient Substances 0.000 description 4
229920001223 polyethylene glycol Polymers 0.000 description 4
238000011533 pre-incubation Methods 0.000 description 4
239000003755 preservative agent Substances 0.000 description 4
230000004850 protein–protein interaction Effects 0.000 description 4
238000011160 research Methods 0.000 description 4
241000894007 species Species 0.000 description 4
239000003381 stabilizer Substances 0.000 description 4
239000005720 sucrose Substances 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
230000004083 survival effect Effects 0.000 description 4
239000003981 vehicle Substances 0.000 description 4
230000035899 viability Effects 0.000 description 4
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
241000702421 Dependoparvovirus Species 0.000 description 3
241000283073 Equus caballus Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 3
108091006013 HA-tagged proteins Proteins 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
108091061960 Naked DNA Proteins 0.000 description 3
241000288906 Primates Species 0.000 description 3
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
241000283984 Rodentia Species 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
229920001615 Tragacanth Polymers 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
241000700605 Viruses Species 0.000 description 3
239000002253 acid Substances 0.000 description 3
238000010171 animal model Methods 0.000 description 3
239000003963 antioxidant agent Substances 0.000 description 3
235000006708 antioxidants Nutrition 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 3
235000019445 benzyl alcohol Nutrition 0.000 description 3
230000004071 biological effect Effects 0.000 description 3
238000001815 biotherapy Methods 0.000 description 3
230000000903 blocking effect Effects 0.000 description 3
230000005907 cancer growth Effects 0.000 description 3
231100000504 carcinogenesis Toxicity 0.000 description 3
238000010609 cell counting kit-8 assay Methods 0.000 description 3
230000022131 cell cycle Effects 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
230000005757 colony formation Effects 0.000 description 3
230000001268 conjugating effect Effects 0.000 description 3
125000000151 cysteine group Chemical class N[C@@H](CS)C(=O)* 0.000 description 3
239000005547 deoxyribonucleotide Substances 0.000 description 3
238000003745 diagnosis Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
238000010790 dilution Methods 0.000 description 3
239000012895 dilution Substances 0.000 description 3
239000003995 emulsifying agent Substances 0.000 description 3
230000004927 fusion Effects 0.000 description 3
238000001476 gene delivery Methods 0.000 description 3
238000007429 general method Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
239000003102 growth factor Substances 0.000 description 3
210000003958 hematopoietic stem cell Anatomy 0.000 description 3
238000004128 high performance liquid chromatography Methods 0.000 description 3
238000002744 homologous recombination Methods 0.000 description 3
230000006801 homologous recombination Effects 0.000 description 3
102000048412 human PCLAF Human genes 0.000 description 3
238000011532 immunohistochemical staining Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
238000007918 intramuscular administration Methods 0.000 description 3
239000008101 lactose Substances 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
235000010355 mannitol Nutrition 0.000 description 3
239000012528 membrane Substances 0.000 description 3
238000006386 neutralization reaction Methods 0.000 description 3
210000002797 pancreatic ductal cell Anatomy 0.000 description 3
239000008177 pharmaceutical agent Substances 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
238000000746 purification Methods 0.000 description 3
238000001959 radiotherapy Methods 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
230000000241 respiratory effect Effects 0.000 description 3
230000004044 response Effects 0.000 description 3
230000002441 reversible effect Effects 0.000 description 3
238000012216 screening Methods 0.000 description 3
229960002920 sorbitol Drugs 0.000 description 3
238000007920 subcutaneous administration Methods 0.000 description 3
239000004094 surface-active agent Substances 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
230000004614 tumor growth Effects 0.000 description 3
230000003612 virological effect Effects 0.000 description 3
HSTOKWSFWGCZMH-UHFFFAOYSA-N 3,3'-diaminobenzidine Chemical compound C1=C(N)C(N)=CC=C1C1=CC=C(N)C(N)=C1 HSTOKWSFWGCZMH-UHFFFAOYSA-N 0.000 description 2
KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
208000002109 Argyria Diseases 0.000 description 2
241000416162 Astragalus gummifer Species 0.000 description 2
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
238000009010 Bradford assay Methods 0.000 description 2
208000005623 Carcinogenesis Diseases 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
101710205889 Cytochrome b562 Proteins 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
108010041986 DNA Vaccines Proteins 0.000 description 2
230000033616 DNA repair Effects 0.000 description 2
101710160937 DNA replication protein Proteins 0.000 description 2
230000006820 DNA synthesis Effects 0.000 description 2
229940021995 DNA vaccine Drugs 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
102000007260 Deoxyribonuclease I Human genes 0.000 description 2
108010008532 Deoxyribonuclease I Proteins 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
102100031780 Endonuclease Human genes 0.000 description 2
LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010070675 Glutathione transferase Proteins 0.000 description 2
102000005720 Glutathione transferase Human genes 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 2
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 2
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 2
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
208000008839 Kidney Neoplasms Diseases 0.000 description 2
241000283953 Lagomorpha Species 0.000 description 2
235000010643 Leucaena leucocephala Nutrition 0.000 description 2
240000007472 Leucaena leucocephala Species 0.000 description 2
102000019298 Lipocalin Human genes 0.000 description 2
108050006654 Lipocalin Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
241000282553 Macaca Species 0.000 description 2
101710175625 Maltose/maltodextrin-binding periplasmic protein Proteins 0.000 description 2
241001529936 Murinae Species 0.000 description 2
101710163270 Nuclease Proteins 0.000 description 2
101710150826 PCNA-associated factor Proteins 0.000 description 2
238000012408 PCR amplification Methods 0.000 description 2
241000282579 Pan Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000002202 Polyethylene glycol Substances 0.000 description 2
HCBIBCJNVBAKAB-UHFFFAOYSA-N Procaine hydrochloride Chemical compound Cl.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 HCBIBCJNVBAKAB-UHFFFAOYSA-N 0.000 description 2
206010036790 Productive cough Diseases 0.000 description 2
102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
108010076504 Protein Sorting Signals Proteins 0.000 description 2
102000000574 RNA-Induced Silencing Complex Human genes 0.000 description 2
108010016790 RNA-Induced Silencing Complex Proteins 0.000 description 2
239000012980 RPMI-1640 medium Substances 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
102000039471 Small Nuclear RNA Human genes 0.000 description 2
108091081024 Start codon Proteins 0.000 description 2
208000024313 Testicular Neoplasms Diseases 0.000 description 2
108091036066 Three prime untranslated region Proteins 0.000 description 2
DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
241000251539 Vertebrata <Metazoa> Species 0.000 description 2
230000004913 activation Effects 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
208000009956 adenocarcinoma Diseases 0.000 description 2
239000000443 aerosol Substances 0.000 description 2
235000010443 alginic acid Nutrition 0.000 description 2
239000000783 alginic acid Substances 0.000 description 2
229920000615 alginic acid Polymers 0.000 description 2
229960001126 alginic acid Drugs 0.000 description 2
150000004781 alginic acids Chemical class 0.000 description 2
230000004075 alteration Effects 0.000 description 2
230000003321 amplification Effects 0.000 description 2
229940035676 analgesics Drugs 0.000 description 2
239000000730 antalgic agent Substances 0.000 description 2
230000002424 anti-apoptotic effect Effects 0.000 description 2
230000001857 anti-mycotic effect Effects 0.000 description 2
230000000890 antigenic effect Effects 0.000 description 2
239000002543 antimycotic Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
229960002903 benzyl benzoate Drugs 0.000 description 2
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000003115 biocidal effect Effects 0.000 description 2
210000000601 blood cell Anatomy 0.000 description 2
239000000872 buffer Substances 0.000 description 2
210000004899 c-terminal region Anatomy 0.000 description 2
230000036952 cancer formation Effects 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000002701 cell growth assay Methods 0.000 description 2
239000013592 cell lysate Substances 0.000 description 2
238000001516 cell proliferation assay Methods 0.000 description 2
239000001913 cellulose Substances 0.000 description 2
229920002678 cellulose Polymers 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
238000004590 computer program Methods 0.000 description 2
238000012790 confirmation Methods 0.000 description 2
239000013068 control sample Substances 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
239000013078 crystal Substances 0.000 description 2
238000012325 curative resection Methods 0.000 description 2
235000018417 cysteine Nutrition 0.000 description 2
210000000805 cytoplasm Anatomy 0.000 description 2
238000006731 degradation reaction Methods 0.000 description 2
238000004925 denaturation Methods 0.000 description 2
230000036425 denaturation Effects 0.000 description 2
239000000539 dimer Substances 0.000 description 2
239000002270 dispersing agent Substances 0.000 description 2
238000009509 drug development Methods 0.000 description 2
238000004520 electroporation Methods 0.000 description 2
230000001804 emulsifying effect Effects 0.000 description 2
239000000839 emulsion Substances 0.000 description 2
238000009558 endoscopic ultrasound Methods 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
210000000981 epithelium Anatomy 0.000 description 2
230000002349 favourable effect Effects 0.000 description 2
210000004700 fetal blood Anatomy 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
238000000684 flow cytometry Methods 0.000 description 2
GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 2
229960002949 fluorouracil Drugs 0.000 description 2
235000013355 food flavoring agent Nutrition 0.000 description 2
238000013467 fragmentation Methods 0.000 description 2
238000006062 fragmentation reaction Methods 0.000 description 2
230000030279 gene silencing Effects 0.000 description 2
239000008103 glucose Substances 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
230000036541 health Effects 0.000 description 2
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
210000004201 immune sera Anatomy 0.000 description 2
229940042743 immune sera Drugs 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
230000002055 immunohistochemical effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000006698 induction Effects 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
206010022000 influenza Diseases 0.000 description 2
238000001802 infusion Methods 0.000 description 2
230000002452 interceptive effect Effects 0.000 description 2
238000001361 intraarterial administration Methods 0.000 description 2
238000004255 ion exchange chromatography Methods 0.000 description 2
210000004153 islets of langerhan Anatomy 0.000 description 2
239000000644 isotonic solution Substances 0.000 description 2
201000010982 kidney cancer Diseases 0.000 description 2
238000002372 labelling Methods 0.000 description 2
230000000670 limiting effect Effects 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
239000006166 lysate Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
230000003211 malignant effect Effects 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
230000001394 metastastic effect Effects 0.000 description 2
206010061289 metastatic neoplasm Diseases 0.000 description 2
108091070501 miRNA Proteins 0.000 description 2
239000002679 microRNA Substances 0.000 description 2
239000003094 microcapsule Substances 0.000 description 2
239000011859 microparticle Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000012544 monitoring process Methods 0.000 description 2
238000000465 moulding Methods 0.000 description 2
239000002736 nonionic surfactant Substances 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
235000015097 nutrients Nutrition 0.000 description 2
150000002894 organic compounds Chemical class 0.000 description 2
238000007911 parenteral administration Methods 0.000 description 2
239000008188 pellet Substances 0.000 description 2
230000000149 penetrating effect Effects 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
229940021222 peritoneal dialysis isotonic solution Drugs 0.000 description 2
239000008363 phosphate buffer Substances 0.000 description 2
150000004713 phosphodiesters Chemical class 0.000 description 2
229950008882 polysorbate Drugs 0.000 description 2
229920000136 polysorbate Polymers 0.000 description 2
229960001309 procaine hydrochloride Drugs 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
235000013772 propylene glycol Nutrition 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
230000005855 radiation Effects 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
239000000376 reactant Substances 0.000 description 2
230000008439 repair process Effects 0.000 description 2
238000002271 resection Methods 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
238000009589 serological test Methods 0.000 description 2
239000008159 sesame oil Substances 0.000 description 2
235000011803 sesame oil Nutrition 0.000 description 2
238000002741 site-directed mutagenesis Methods 0.000 description 2
108091029842 small nuclear ribonucleic acid Proteins 0.000 description 2
239000007974 sodium acetate buffer Substances 0.000 description 2
235000012424 soybean oil Nutrition 0.000 description 2
239000003549 soybean oil Substances 0.000 description 2
239000007921 spray Substances 0.000 description 2
210000003802 sputum Anatomy 0.000 description 2
208000024794 sputum Diseases 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
150000005846 sugar alcohols Polymers 0.000 description 2
229940104230 thymidine Drugs 0.000 description 2
230000017423 tissue regeneration Effects 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
230000001131 transforming effect Effects 0.000 description 2
230000004565 tumor cell growth Effects 0.000 description 2
239000000439 tumor marker Substances 0.000 description 2
241001430294 unidentified retrovirus Species 0.000 description 2
210000002700 urine Anatomy 0.000 description 2
229960005486 vaccine Drugs 0.000 description 2
238000001086 yeast two-hybrid system Methods 0.000 description 2
LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
101150084750 1 gene Proteins 0.000 description 1
HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
MXXGKASZZLDWPV-UHFFFAOYSA-N 5-methylpyrimidine Chemical group CC1=CN=C=N[CH]1 MXXGKASZZLDWPV-UHFFFAOYSA-N 0.000 description 1
LMEHJKJEPRYEEB-UHFFFAOYSA-N 5-prop-1-ynylpyrimidine Chemical compound CC#CC1=CN=CN=C1 LMEHJKJEPRYEEB-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
241001316595 Acris Species 0.000 description 1
229920001817 Agar Polymers 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
102000002260 Alkaline Phosphatase Human genes 0.000 description 1
108020004774 Alkaline Phosphatase Proteins 0.000 description 1
108090000672 Annexin A5 Proteins 0.000 description 1
102000004121 Annexin A5 Human genes 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
241000167854 Bourreria succulenta Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
108010076667 Caspases Proteins 0.000 description 1
102000011727 Caspases Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
108010031896 Cell Cycle Proteins Proteins 0.000 description 1
102000005483 Cell Cycle Proteins Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
206010009944 Colon cancer Diseases 0.000 description 1
206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
108020004635 Complementary DNA Proteins 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
241000699800 Cricetinae Species 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
239000004338 Dichlorodifluoromethane Substances 0.000 description 1
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
239000006144 Dulbecco’s modiﬁed Eagle's medium Substances 0.000 description 1
102000001301 EGF receptor Human genes 0.000 description 1
108060006698 EGF receptor Proteins 0.000 description 1
208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102100023882 Endoribonuclease ZC3H12A Human genes 0.000 description 1
101710112715 Endoribonuclease ZC3H12A Proteins 0.000 description 1
108700039887 Essential Genes Proteins 0.000 description 1
241000533867 Fordia Species 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101000945496 Homo sapiens Proliferation marker protein Ki-67 Proteins 0.000 description 1
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
108700005091 Immunoglobulin Genes Proteins 0.000 description 1
102000006496 Immunoglobulin Heavy Chains Human genes 0.000 description 1
108010019476 Immunoglobulin Heavy Chains Proteins 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
108090001005 Interleukin-6 Proteins 0.000 description 1
108091092195 Intron Proteins 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
239000012097 Lipofectamine 2000 Substances 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
235000019759 Maize starch Nutrition 0.000 description 1
206010064912 Malignant transformation Diseases 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
241000711408 Murine respirovirus Species 0.000 description 1
101100368144 Mus musculus Synb gene Proteins 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
101001059625 Mytilus californianus Fibronectin type III domain-containing protein Proteins 0.000 description 1
229910020700 Na3VO4 Inorganic materials 0.000 description 1
108700019961 Neoplasm Genes Proteins 0.000 description 1
102000048850 Neoplasm Genes Human genes 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091092724 Noncoding DNA Proteins 0.000 description 1
108091005461 Nucleic proteins Proteins 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
108010074467 Pancreatitis-Associated Proteins Proteins 0.000 description 1
102000008080 Pancreatitis-Associated Proteins Human genes 0.000 description 1
108090000526 Papain Proteins 0.000 description 1
241000282520 Papio Species 0.000 description 1
241000282515 Papio hamadryas Species 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
229930040373 Paraformaldehyde Natural products 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
108091000080 Phosphotransferase Proteins 0.000 description 1
241000276498 Pollachius virens Species 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
102100034836 Proliferation marker protein Ki-67 Human genes 0.000 description 1
101800004937 Protein C Proteins 0.000 description 1
102000017975 Protein C Human genes 0.000 description 1
102000014450 RNA Polymerase III Human genes 0.000 description 1
108010078067 RNA Polymerase III Proteins 0.000 description 1
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
238000010240 RT-PCR analysis Methods 0.000 description 1
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
102000003661 Ribonuclease III Human genes 0.000 description 1
108010057163 Ribonuclease III Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
230000018199 S phase Effects 0.000 description 1
101150041689 SLC25A5 gene Proteins 0.000 description 1
101800001700 Saposin-D Proteins 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000282887 Suidae Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
108010018242 Transcription Factor AP-1 Proteins 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
102100023132 Transcription factor Jun Human genes 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
239000013504 Triton X-100 Substances 0.000 description 1
229920004890 Triton X-100 Polymers 0.000 description 1
108091023045 Untranslated Region Proteins 0.000 description 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
210000000683 abdominal cavity Anatomy 0.000 description 1
238000011481 absorbance measurement Methods 0.000 description 1
LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000000853 adhesive Substances 0.000 description 1
230000001070 adhesive effect Effects 0.000 description 1
238000005377 adsorption chromatography Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
230000009824 affinity maturation Effects 0.000 description 1
239000008272 agar Substances 0.000 description 1
235000010419 agar Nutrition 0.000 description 1
229940040563 agaric acid Drugs 0.000 description 1
239000011543 agarose gel Substances 0.000 description 1
230000002776 aggregation Effects 0.000 description 1
238000004220 aggregation Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
150000001298 alcohols Chemical class 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
210000004381 amniotic fluid Anatomy 0.000 description 1
239000003708 ampul Substances 0.000 description 1
208000036878 aneuploidy Diseases 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
125000000129 anionic group Chemical group 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
230000003527 anti-angiogenesis Effects 0.000 description 1
230000006909 anti-apoptosis Effects 0.000 description 1
230000001093 anti-cancer Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
229940041181 antineoplastic drug Drugs 0.000 description 1
238000003782 apoptosis assay Methods 0.000 description 1
239000000305 astragalus gummifer gum Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
239000013602 bacteriophage vector Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
229940049706 benzodiazepine Drugs 0.000 description 1
125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 description 1
150000003938 benzyl alcohols Chemical class 0.000 description 1
DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
229960000397 bevacizumab Drugs 0.000 description 1
239000012620 biological material Substances 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
201000000053 blastoma Diseases 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
210000001185 bone marrow Anatomy 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
210000000481 breast Anatomy 0.000 description 1
239000007853 buffer solution Substances 0.000 description 1
210000004900 c-terminal fragment Anatomy 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000001569 carbon dioxide Substances 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000002091 cationic group Chemical group 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
230000006369 cell cycle progression Effects 0.000 description 1
230000030833 cell death Effects 0.000 description 1
239000002771 cell marker Substances 0.000 description 1
230000007541 cellular toxicity Effects 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
210000001175 cerebrospinal fluid Anatomy 0.000 description 1
238000012412 chemical coupling Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
235000019693 cherries Nutrition 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
239000007979 citrate buffer Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
229940110456 cocoa butter Drugs 0.000 description 1
235000019868 cocoa butter Nutrition 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
239000007891 compressed tablet Substances 0.000 description 1
238000007906 compression Methods 0.000 description 1
230000006835 compression Effects 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
238000002591 computed tomography Methods 0.000 description 1
238000009833 condensation Methods 0.000 description 1
230000005494 condensation Effects 0.000 description 1
238000010276 construction Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
230000001276 controlling effect Effects 0.000 description 1
NKLPQNGYXWVELD-UHFFFAOYSA-M coomassie brilliant blue Chemical compound [Na+].C1=CC(OCC)=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C=CC(=CC=2)N(CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=C1 NKLPQNGYXWVELD-UHFFFAOYSA-M 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
210000004395 cytoplasmic granule Anatomy 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002950 deficient Effects 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
229960003964 deoxycholic acid Drugs 0.000 description 1
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 1
125000002637 deoxyribonucleotide group Chemical group 0.000 description 1
230000002074 deregulated effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
238000002059 diagnostic imaging Methods 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
229960003983 diphtheria toxoid Drugs 0.000 description 1
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
238000001493 electron microscopy Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
201000008184 embryoma Diseases 0.000 description 1
238000004945 emulsification Methods 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
201000011523 endocrine gland cancer Diseases 0.000 description 1
238000007459 endoscopic retrograde cholangiopancreatography Methods 0.000 description 1
210000001163 endosome Anatomy 0.000 description 1
108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
239000000284 extract Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
125000000524 functional group Chemical group 0.000 description 1
230000000799 fusogenic effect Effects 0.000 description 1
239000007789 gas Substances 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000002523 gelfiltration Methods 0.000 description 1
230000037440 gene silencing effect Effects 0.000 description 1
102000034356 gene-regulatory proteins Human genes 0.000 description 1
108091006104 gene-regulatory proteins Proteins 0.000 description 1
230000002068 genetic effect Effects 0.000 description 1
210000001280 germinal center Anatomy 0.000 description 1
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
210000003494 hepatocyte Anatomy 0.000 description 1
125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 1
210000004754 hybrid cell Anatomy 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
238000003384 imaging method Methods 0.000 description 1
230000001900 immune effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000028802 immunoglobulin-mediated neutralization Effects 0.000 description 1
238000003364 immunohistochemistry Methods 0.000 description 1
238000012744 immunostaining Methods 0.000 description 1
229960003444 immunosuppressant agent Drugs 0.000 description 1
239000003018 immunosuppressive agent Substances 0.000 description 1
238000007901 in situ hybridization Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
230000010354 integration Effects 0.000 description 1
230000010468 interferon response Effects 0.000 description 1
210000004347 intestinal mucosa Anatomy 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
230000002147 killing effect Effects 0.000 description 1
238000001001 laser micro-dissection Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000001638 lipofection Methods 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
230000001050 lubricating effect Effects 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
230000001926 lymphatic effect Effects 0.000 description 1
230000006674 lysosomal degradation Effects 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000036212 malign transformation Effects 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
238000004949 mass spectrometry Methods 0.000 description 1
238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
210000003593 megakaryocyte Anatomy 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
210000004779 membrane envelope Anatomy 0.000 description 1
102000006240 membrane receptors Human genes 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
238000012775 microarray technology Methods 0.000 description 1
230000000813 microbial effect Effects 0.000 description 1
238000000520 microinjection Methods 0.000 description 1
238000002715 modification method Methods 0.000 description 1
239000003607 modifier Substances 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
229940126619 mouse monoclonal antibody Drugs 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
108091005763 multidomain proteins Proteins 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000000663 muscle cell Anatomy 0.000 description 1
210000004898 n-terminal fragment Anatomy 0.000 description 1
239000006199 nebulizer Substances 0.000 description 1
230000006654 negative regulation of apoptotic process Effects 0.000 description 1
230000017095 negative regulation of cell growth Effects 0.000 description 1
230000035407 negative regulation of cell proliferation Effects 0.000 description 1
210000000440 neutrophil Anatomy 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
239000002687 nonaqueous vehicle Substances 0.000 description 1
231100000956 nontoxicity Toxicity 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000007826 nucleic acid assay Methods 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
239000003921 oil Substances 0.000 description 1
235000019198 oils Nutrition 0.000 description 1
238000002515 oligonucleotide synthesis Methods 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
125000000885 organic scaffold group Chemical group 0.000 description 1
210000004798 organs belonging to the digestive system Anatomy 0.000 description 1
229940043515 other immunoglobulins in atc Drugs 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
229940055729 papain Drugs 0.000 description 1
235000019834 papain Nutrition 0.000 description 1
229920002866 paraformaldehyde Polymers 0.000 description 1
239000002245 particle Substances 0.000 description 1
235000010603 pastilles Nutrition 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001575 pathological effect Effects 0.000 description 1
QGVYYLZOAMMKAH-UHFFFAOYSA-N pegnivacogin Chemical compound COCCOC(=O)NCCCCC(NC(=O)OCCOC)C(=O)NCCCCCCOP(=O)(O)O QGVYYLZOAMMKAH-UHFFFAOYSA-N 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
229940083251 peripheral vasodilators purine derivative Drugs 0.000 description 1
238000002823 phage display Methods 0.000 description 1
102000020233 phosphotransferase Human genes 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000010773 plant oil Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
238000007694 polyacrylamide gel isoelectric focusing Methods 0.000 description 1
229920002704 polyhistidine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
238000010837 poor prognosis Methods 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
230000002980 postoperative effect Effects 0.000 description 1
229920001592 potato starch Polymers 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
230000005522 programmed cell death Effects 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000000644 propagated effect Effects 0.000 description 1
239000003380 propellant Substances 0.000 description 1
XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
238000000159 protein binding assay Methods 0.000 description 1
229960000856 protein c Drugs 0.000 description 1
238000012514 protein characterization Methods 0.000 description 1
238000001742 protein purification Methods 0.000 description 1
238000001243 protein synthesis Methods 0.000 description 1
230000017854 proteolysis Effects 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
239000001397 quillaja saponaria molina bark Substances 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
230000010837 receptor-mediated endocytosis Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
239000013074 reference sample Substances 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
108010008790 ribosomal phosphoprotein P1 Proteins 0.000 description 1
229940100486 rice starch Drugs 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
210000003296 saliva Anatomy 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
229930182490 saponin Natural products 0.000 description 1
150000007949 saponins Chemical class 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000006152 selective media Substances 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
230000000405 serological effect Effects 0.000 description 1
239000012679 serum free medium Substances 0.000 description 1
230000011664 signaling Effects 0.000 description 1
230000001743 silencing effect Effects 0.000 description 1
229910052709 silver Inorganic materials 0.000 description 1
239000004332 silver Substances 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
238000000528 statistical test Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
238000003860 storage Methods 0.000 description 1
238000012916 structural analysis Methods 0.000 description 1
238000010254 subcutaneous injection Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
239000000758 substrate Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000013589 supplement Substances 0.000 description 1
239000000829 suppository Substances 0.000 description 1
230000001629 suppression Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
238000013268 sustained release Methods 0.000 description 1
239000012730 sustained-release form Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009897 systematic effect Effects 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
231100001274 therapeutic index Toxicity 0.000 description 1
229940126622 therapeutic monoclonal antibody Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 1
208000037816 tissue injury Diseases 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000000699 topical effect Effects 0.000 description 1
239000003053 toxin Substances 0.000 description 1
231100000765 toxin Toxicity 0.000 description 1
108700012359 toxins Proteins 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
230000009466 transformation Effects 0.000 description 1
230000009261 transgenic effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
238000011277 treatment modality Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 1
229940029284 trichlorofluoromethane Drugs 0.000 description 1
IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
230000001228 trophic effect Effects 0.000 description 1
201000008827 tuberculosis Diseases 0.000 description 1
230000005748 tumor development Effects 0.000 description 1
238000013042 tunel staining Methods 0.000 description 1
238000000108 ultra-filtration Methods 0.000 description 1
238000002604 ultrasonography Methods 0.000 description 1
241001529453 unidentified herpesvirus Species 0.000 description 1
DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
229940045145 uridine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1
229940100445 wheat starch Drugs 0.000 description 1
239000009637 wintergreen oil Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2525/00—Reactions involving modified oligonucleotides, nucleic acids, or nucleotides
- C12Q2525/10—Modifications characterised by
- C12Q2525/207—Modifications characterised by siRNA, miRNA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Zoology (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Wood Science & Technology (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Physics & Mathematics (AREA)
Oncology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Pathology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Epidemiology (AREA)
Plant Pathology (AREA)
Reproductive Health (AREA)
Pregnancy & Childbirth (AREA)
Endocrinology (AREA)

CA 2660516 2006-08-18 2007-08-08 Traitement ou prevention de cancers surexprimant le reg4 ou le kiaa0101 Abandoned CA2660516A1 (fr)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US83864906P	2006-08-18	2006-08-18
US83874906P	2006-08-18	2006-08-18
US60/838,749		2006-08-18
US60/838,649		2006-08-18
PCT/JP2007/065873 WO2008020596A2 (fr)	2006-08-18	2007-08-08	Traitement ou prévention de cancers surexprimant le reg4 ou le kiaa0101

Publications (1)

Publication Number	Publication Date
CA2660516A1 true CA2660516A1 (fr)	2008-02-21

Family

ID=38935815

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2660516 Abandoned CA2660516A1 (fr)	2006-08-18	2007-08-08	Traitement ou prevention de cancers surexprimant le reg4 ou le kiaa0101

Country Status (7)

Country	Link
EP (1)	EP2059593A2 (fr)
JP (1)	JP2010501161A (fr)
KR (1)	KR20090040391A (fr)
BR (1)	BRPI0715763A2 (fr)
CA (1)	CA2660516A1 (fr)
RU (1)	RU2009109692A (fr)
WO (1)	WO2008020596A2 (fr)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
KR101196415B1 (ko)	2007-01-04	2012-11-02	에스케이케미칼주식회사	백색도가 높은 폴리아릴렌설파이드 수지 및 이의 제조방법
US7960139B2 (en)	2007-03-23	2011-06-14	Academia Sinica	Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells
WO2010009271A2 (fr)	2008-07-15	2010-01-21	Academia Sinica	Matrices de glycane sur des lames de verre revêtues d’aluminium de type ptfe et procédés associés
US8722875B2 (en)	2008-09-23	2014-05-13	Silence Therapeutics Gmbh	Means for inhibiting the expression of Orc-1
US11377485B2 (en)	2009-12-02	2022-07-05	Academia Sinica	Methods for modifying human antibodies by glycan engineering
US10087236B2 (en)	2009-12-02	2018-10-02	Academia Sinica	Methods for modifying human antibodies by glycan engineering
WO2011130332A1 (fr)	2010-04-12	2011-10-20	Academia Sinica	Puces au glycane pour la recherche par criblage haut débit de virus
NZ603972A (en)	2010-05-11	2014-11-28	Aveo Pharmaceuticals Inc	Anti-fgfr2 antibodies
US10130714B2 (en)	2012-04-14	2018-11-20	Academia Sinica	Enhanced anti-influenza agents conjugated with anti-inflammatory activity
AU2013306098A1 (en)	2012-08-18	2015-02-12	Academia Sinica	Cell-permeable probes for identification and imaging of sialidases
EP3013365B1 (fr)	2013-06-26	2019-06-05	Academia Sinica	Antigènes rm2 et leur utilisation
WO2014210564A1 (fr)	2013-06-27	2014-12-31	Academia Sinica	Conjugués de glycane et leur utilisation
CA2923579C (fr)	2013-09-06	2023-09-05	Academia Sinica	Activation des cellules humaines inkt a l'aide de glycolipides ayant des groupes glycolsyles modifies
US9982041B2 (en)	2014-01-16	2018-05-29	Academia Sinica	Compositions and methods for treatment and detection of cancers
US10150818B2 (en)	2014-01-16	2018-12-11	Academia Sinica	Compositions and methods for treatment and detection of cancers
EP3129767B1 (fr)	2014-03-27	2021-09-01	Academia Sinica	Composés de marquage réactifs et leurs utilisations
JP7062361B2 (ja)	2014-05-27	2022-05-06	アカデミアシニカ	抗ｈｅｒ２糖操作抗体群およびその使用
AU2015267052A1 (en)	2014-05-27	2016-12-15	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
US10118969B2 (en)	2014-05-27	2018-11-06	Academia Sinica	Compositions and methods relating to universal glycoforms for enhanced antibody efficacy
JP7063538B2 (ja)	2014-05-28	2022-05-09	アカデミアシニカ	抗ＴＮＦα糖操作抗体群およびその使用
KR101779147B1 (ko) *	2014-07-04	2017-09-20	연세대학교 산학협력단	Kiaa1199를 이용한 췌장암의 진단 또는 치료용 조성물
WO2016040369A2 (fr)	2014-09-08	2016-03-17	Academia Sinica	Activation des cellules inkt humaines par des glycolipides
US10495645B2 (en)	2015-01-16	2019-12-03	Academia Sinica	Cancer markers and methods of use thereof
US9975965B2 (en)	2015-01-16	2018-05-22	Academia Sinica	Compositions and methods for treatment and detection of cancers
TW201808978A (zh)	2016-03-08	2018-03-16	中央研究院	N-聚醣及其陣列之模組化合成方法
AU2017316663B2 (en)	2016-08-22	2024-02-22	CHO Pharma Inc.	Antibodies, binding fragments, and methods of use
RU2759045C1 (ru) *	2020-12-22	2021-11-09	Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ)	Способ комплексного лечения местнораспространенной протоковой аденокарциномы поджелудочной железы

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004003144A2 (fr) *	2002-07-01	2004-01-08	Human Genome Sciences, Inc.	Anticorps qui se lient specifiquement a reg iv
ES2320443T3 (es) *	2002-09-30	2009-05-22	Oncotherapy Science, Inc.	Genes y polipeptidos relacionados con canceres pancreaticos humanos.
US7510708B2 (en) *	2003-04-14	2009-03-31	Washington University	Disruption of the REG pathway
WO2006099539A1 (fr) *	2005-03-15	2006-09-21	The Regents Of The University Of California	Reg iv, cible pour le diagnostic et le traitement du cancer
JP2009528507A (ja) *	2006-03-02	2009-08-06	オンコセラピー・サイエンス株式会社	Ｒｅｇ４タンパク質を用いて膵癌を診断する方法

2007
- 2007-08-08 CA CA 2660516 patent/CA2660516A1/fr not_active Abandoned
- 2007-08-08 EP EP07792516A patent/EP2059593A2/fr not_active Withdrawn
- 2007-08-08 KR KR20097005475A patent/KR20090040391A/ko not_active Application Discontinuation
- 2007-08-08 WO PCT/JP2007/065873 patent/WO2008020596A2/fr active Application Filing
- 2007-08-08 JP JP2009524366A patent/JP2010501161A/ja active Pending
- 2007-08-08 BR BRPI0715763 patent/BRPI0715763A2/pt not_active Application Discontinuation
- 2007-08-08 RU RU2009109692/10A patent/RU2009109692A/ru unknown

Also Published As

Publication number	Publication date
JP2010501161A (ja)	2010-01-21
WO2008020596A2 (fr)	2008-02-21
KR20090040391A (ko)	2009-04-23
EP2059593A2 (fr)	2009-05-20
BRPI0715763A2 (pt)	2013-09-24
RU2009109692A (ru)	2010-09-27
WO2008020596A3 (fr)	2008-06-12

Publication	Publication Date	Title
CA2660516A1 (fr)	2008-02-21	Traitement ou prevention de cancers surexprimant le reg4 ou le kiaa0101
CN101528926A (zh)	2009-09-09	过表达reg4或kiaa0101的癌症的治疗或预防
KR102167550B1 (ko)	2020-10-19	Dll3 결합 시약을 포함하는 암에 대한 치료적 및 진단적 타겟
US7959923B2 (en)	2011-06-14	Method for treating cancer using anti-Wnt2 monoclonal antibodies and siRNA
TW200920406A (en)	2009-05-16	EBI3, DLX5, NPTX1 and CDKN3 for target genes of lung cancer therapy and diagnosis
EP2723350B1 (fr)	2017-11-01	Nouvelles utilisations d'inhibiteurs du gène nanog et procédés associés
EP1854473A1 (fr)	2007-11-14	Agent préventif/thérapeutique pour le cancer
CN107249636B (zh)	2023-07-28	以ckap4作为靶分子的抗肿瘤剂
JP2009523409A (ja)	2009-06-25	がん治療用およびがん診断用の組成物および方法
EP2596025B1 (fr)	2018-06-20	Méthodes de gestion du cancer ciblant co-029
US9944713B2 (en)	2018-04-17	Antibody specific to the AIMP2-DX2
US20170269093A1 (en)	2017-09-21	Methods for identifying and treating invasive/metastatic cancers
US20160075752A1 (en)	2016-03-17	B-type plexin antagonists and uses thereof
US20080267951A1 (en)	2008-10-30	Methods for Treating Cancer Using Agents That Inhibit Wnt16 Signaling
US20240043557A1 (en)	2024-02-08	A platform to obtain monoclonal antibodies directed against processed tumor-specific antigens
US20110027297A1 (en)	2011-02-03	Methods Involving MS4A12 and Agents Targeting MS4A12 for Therapy, Diagnosis and Testing
US20110039789A1 (en)	2011-02-17	Use of Huntingtin Protein for the Diagnosis and the Treatment of Cancer
WO2019039439A1 (fr)	2019-02-28	Protéine hybride de protéine dctn1 et de protéine ret
US11136368B2 (en)	2021-10-05	Cancer treatment using CX26 blocking peptides
KR101796091B1 (ko)	2017-11-10	카복실 말단 조절 단백질을 포함하는 두경부암 진단용 바이오 마커 조성물
KR20140042577A (ko)	2014-04-07	암의 예후 예측 및 치료를 위한 ｍａｅｌ의 용도
JP2008509076A (ja)	2008-03-27	ＦＺＤ１０に対するｓｉＲＮＡを用いた滑膜肉腫の治療方法
KR101062167B1 (ko)	2011-09-05	Ｋｉｒ2.2 억제제를 포함하는 암 치료용 조성물
JP2020048426A (ja)	2020-04-02	フリズルド３発現細胞の細胞数増加剤若しくは低下剤、糖尿病予防若しくは治療剤、インスリノーマ予防若しくは治療剤、及びインスリン分泌促進剤若しくは分泌抑制剤よりなる群から選択される少なくとも１つの剤をスクリーニングするためのスクリーニング剤、スクリーニング用キット、及びスクリーニング方法
WO2013059471A1 (fr)	2013-04-25	Compositions et méthodes pour traiter la leucémie

Legal Events

Date	Code	Title	Description
2011-08-08	FZDE	Dead